The European—Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion
Paclitaxel (Taxol) has demonstrated activity in platinum pretreated ovarian cancer [1–]. Because of severe hypersensitivity reactions seen early in the evaluation of the drug, treatment protocols were developed which gave paclitaxel over 24 hours together with antiallergic premedication. This maneuver resulted in a decrease in the frequency of severe reactions, although many patients continued to experience mild symptoms . Shorter outpatient infusions with premedication had not been evaluated and the question of their safety remained unknown.
KeywordsOvarian Cancer Hypersensitivity Reaction Epithelial Ovarian Cancer Severe Reaction Advanced Ovarian Cancer
Unable to display preview. Download preview PDF.
- 1.Thigpen, T., Blessing, J., Ball, H. et al (1990) Phase II trial of taxol as second-line therapy for ovarian cancer: A Gynecologic Oncology Group Study. Proc. Am. Soc. Clin. Oncol, 9 156.Google Scholar